Thursday, May 5, 2016

BioLight Life Sciences focusing on ophthalmic portfolio

BioLight Life Sciences focusing on ophthalmic portfolio

December 8, 2015 by · Leave a Comment 

Tweet BioLight Life Sciences Investments (OTCQX:BLGTY; TASE:BOLT) is now defining itself as an ophthalmology company after spending several years assembling a cluster of investments in the sector as well as in cancer diagnostics. “We believe there is a huge value potential from the ophthalmic therapeutics and diagnostics we have gathered,” CEO, Suzana Nahum Zilberberg, says […]

TearLab Q3 revenue climbs 27%

TearLab Q3 revenue climbs 27%

November 5, 2015 by · Leave a Comment 

Tweet Third quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) rose 27% to $6.6-million from $5.2-million a year ago. A net total of 228 TearLab systems were added in the third quarter. “We delivered a strong growth quarter both sequentially and compared with the prior year by expanding our device base and continuing to establish the clinical […]

TearLab Q2 revenue climbs 27%

TearLab Q2 revenue climbs 27%

August 7, 2015 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has reported net revenue of $6.3-million for the second quarter this year, up 27%, from $5-million a year ago. A total of 394 orders for TearLab systems were booked in the second quarter, of which 303 were under the company’s new Flex program and 28 were purchased outside of the U.S. […]

Doctors discuss importance of tear film osmolarity

Doctors discuss importance of tear film osmolarity

August 4, 2015 by · Leave a Comment 

Tweet In an Eyetube.net video segment of the CRST Journal Club (Cataract & Refractive Surgery Today), Dr. John Davidson, of Miramar Eye Specialists in Ventura County, CA, and Dr. Jay Pepose, of the Pepose Vision Institute in St. Louis, discuss the importance of optimizing the ocular surface prior to premium intraocular lens surgery. Dr. Pepose […]

BioLight in DES diagnostic collaboration with Ora

BioLight in DES diagnostic collaboration with Ora

June 15, 2015 by · Leave a Comment 

Tweet BioLight Life Sciences Investments (OTCQX:BLGTY; TASE:BOLT) has expanded its relationship with Ora Inc., with the signing of a collaboration agreement to advance the clinical, regulatory and commercial development of BioLight’s TeaRx multi-parameter diagnostic test for dry eye syndrome (DES). BioLight and Ora will jointly fund the clinical study and other activities required to obtain […]

Ocular Therapeutix eyeing sustained drug delivery

Ocular Therapeutix eyeing sustained drug delivery

March 17, 2015 by · Leave a Comment 

Tweet Ocular Therapeutix (NASDAQ:OCUL) is aiming to transform the treatment of eye diseases with sustained-release therapeutics, creating a paradigm shift from frequently administered topical ophthalmic drugs to an entire course of therapy in as little as a single dose. “We have multiple late-stage product candidates based on our proven hydrogel technology platform, addressing the largest […]

BioLight units post positive study results

BioLight units post positive study results

February 2, 2015 by · Leave a Comment 

Tweet BioLight Life Sciences Investments (OTC:BLGTY; TASE:BOLT) has released positive study results from two subsidiaries developing the CellDetect non-invasive test for detecting bladder cancer in urine and the TeaRx diagnostic tests for dry eye. CellDetect successfully achieved the study’s primary endpoint for effectively detecting the recurrence of bladder cancer in subjects with a history of […]

TearLab, Dipexium and Joint in Feltl 2015 Top Idea List

TearLab, Dipexium and Joint in Feltl 2015 Top Idea List

January 5, 2015 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB), Dipexium Pharmaceuticals (NASDAQ:DPRX) and The Joint Corp. (NASDAQ:JYNT) were included in Feltl & Co.’s 2015 Top Idea List released today. Analyst Ben Haynor rates TearLab at “strong buy” with a price target of $5. The stock closed at $2.58 on Friday. TearLab has first-mover advantage in point-of-care diagnostics for dry eye […]

TearLab reports interim results of DED prevalence study in UK

TearLab reports interim results of DED prevalence study in UK

September 4, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has reported interim results of a multi-center dry eye disease (DED) prevalence study being carried out in the UK at four National Health Service (NHS) hospitals.  The study compared the effectiveness of the TearLab Osmolarity test to other traditional methods of diagnosing DED. Conducted under the auspices of the UK’s National […]

Mati Therapeutics gets another U.S. patent

Mati Therapeutics gets another U.S. patent

June 30, 2014 by · Leave a Comment 

Tweet Closely held Mati Therapeutics has received a U.S. patent covering its novel punctal plug delivery system for treatment of ocular indications (PPDS), including certain features for retaining the punctal plug within the nasolacrimal system of the eye during drug elution. The patent is titled, “Nasolacrimal Drainage System Implants For Drug Therapy.” Mati is actively […]

Next Page »

Email Newsletters with Constant Contact
Google+